Clincosm LogoSign in Get a demo

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

Sponsor
Concert Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT04092712
Collaborator
Celerion (Industry)
6
Enrollment
1
Location
1
Arm
15
Actual Duration (Days)
12.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will assess the absorption, metabolism, excretion, mass balance, safety, and tolerability of a single oral administration of [14C]-CTP-543 in healthy male subjects.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
6 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
A Phase 1, Open-label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Oral [14C]-CTP-543 in Healthy Adult Male Subjects
Actual Study Start Date :
Sep 5, 2019
Actual Primary Completion Date :
Sep 11, 2019
Actual Study Completion Date :
Sep 20, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Investigational Product

[14C]-CTP-543

Drug: [14C]-CTP-543
Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution

Outcome Measures

Primary Outcome Measures

  1. Mass balance: Calculation of percent of total radioactivity recovered in urine [From time zero up to 96 hours post-dose following oral administration of [14C]-CTP-543 up to Day 15]

  2. Mass balance: Calculation of percent of total radioactivity recovered in feces [From time zero up to 96 hours post-dose following oral administration of [14C]-CTP-543 up to Day 15]

  3. CTP-543 PK: Cmax [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

    Maximum plasma concentration

  4. CTP-543 PK: Tmax [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

    Time for Cmax

  5. CTP-543 PK: t1/2 [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

  6. CTP-543 PK: AUClast [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

    Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration (Clast)

  7. CTP-543 PK: AUCinf [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

    Area under the plasma concentration time profile from time 0 to infinity

  8. CTP-543 PK: CL/F [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes).

  9. CTP-543 PK: Vz/F [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

    Apparent volume of distribution following oral administration

  10. CTP-543 metabolite PK: Cmax [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

    Maximum plasma concentration

  11. CTP-543 metabolite PK: Tmax [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

    Time for Cmax

  12. CTP-543 metabolite PK: t1/2 [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

  13. CTP-543 metabolite PK: AUC0-last [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

    Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration (Clast)

  14. CTP-543 metabolite PK: AUCinf [Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose]

    Area under the plasma concentration time profile from time 0 to infinity

  15. Total [14C]: urine [Pre-dose up to 336 hours post-dose]

    Total radioactivity excreted into the urine from time zero to the time of last measurable concentration following oral administration of [14C]-CTP-543

  16. Total [14C]: feces [Pre-dose up to 336 hours post-dose]

    Total radioactivity excreted into the feces from time zero to the time of last measurable concentration following oral administration of [14C]-CTP-543

  17. Total radioactivity in whole blood [Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose]

  18. Total radioactivity in plasma [Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose]

Secondary Outcome Measures

  1. Adverse events [Screening up to Day 15]

    Number of adverse events, which are any untoward medical occurrence regardless of attribution to study drug in a participant who received study drug

  2. Number of Participants With Clinically Significant Change From Baseline in Heart Rate [Screening, Pre-dose, 2, 8, 48 hours post-dose]

    Heart rate measured in beats per minute (bpm)

  3. Number of Participants With Clinically Significant Change From Baseline in Blood Pressure [Screening, Pre-dose, 2, 8, 48 hours post-dose]

    Blood pressure measured in millimeters of mercury (mmHg)

  4. Number of Participants With Clinically Significant Change From Baseline in Respiratory Rate [Screening, Pre-dose, 2, 8, 48 hours post-dose]

    Respiratory rate measured in breaths per minute

  5. Number of Participants With Clinically Significant Change From Baseline in Temperature [Screening, Pre-dose, 2, 8, 48 hours post-dose]

    Temperature measured in Celsius (°C)

  6. Number of Participants With Clinically Significant Change From Baseline in Hematology [Screening, Check-in, 8, 24 hours postdose]

  7. Number of Participants With Clinically Significant Change From Baseline in Serum Chemistry [Screening, Check-in, 8, 24 hours postdose]

  8. Number of Participants With Clinically Significant Change From Baseline in Coagulation [Screening, Check-in, 8, 24 hours postdose]

  9. Number of Participants With Clinically Significant Change From Baseline in Urinalysis [Screening, Check-in, 8, 24 hours postdose]

  10. Number of Participants With Clinically Significant Changes to the Physical Examination [Screening up to Day 15]

    Clinically significant changes to the physical examination

  11. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - P Wave [Screening, Pre-dose, 48 hours post-dose]

  12. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - QRS Complex [Screening, Pre-dose, 48 hours post-dose]

  13. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - QT Interval [Screening, Pre-dose, 48 hours post-dose]

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 55 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Healthy male subjects between the ages of 19 and 55 years, inclusive (healthy is determined by medical evaluation, including medical history, full physical examination, vital signs, electrocardiogram, and clinical laboratory tests)

  • Body Mass Index of 18.0 to 32.0 kg/m2

  • Continuous non smoker who has not used nicotine containing products for at least 3 months prior to dosing and throughout the study

Exclusion Criteria:

  • Known immunodeficiency disorder, including positive serology for human immunodeficiency virus (HIV) at screening

  • Infection with hepatitis B or hepatitis C viruses

  • History of irregular bowel movements

  • History of herpes zoster

  • A positive tuberculosis test at screening or history of incompletely treated or untreated tuberculosis

  • History or presence of alcoholism or drug abuse within the past 2 years prior to dosing

  • Participation in another clinical study within 30 days prior to dosing

Contacts and Locations

Locations

Site City State Country Postal Code
1 Celerion Lincoln Nebraska United States 68502

Sponsors and Collaborators

  • Concert Pharmaceuticals
  • Celerion

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Concert Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT04092712
Other Study ID Numbers:
  • CP543.1004
First Posted:
Sep 17, 2019
Last Update Posted:
Sep 25, 2019
Last Verified:
Sep 1, 2019
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Concert Pharmaceuticals
Mass Balance
Radiolabeled
Pharmacokinetics

Study Results

No Results Posted as of Sep 25, 2019